An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

Abstract

A posteriori evidence suggests that radiotherapy to a targeted tumor can elicit an immune-mediated abscopal (ab-scopus, away from the target) effect in non-targeted tumors, when combined with an anti-cytotoxic T-lymphocyte antigen-4 monoclonal (CTLA-4) antibody. Concurrent radiotherapy and ipilimumab (a human monoclonal anti-CTLA-4 antibody) induced immune-mediated abscopal effects in poorly immunogenic pre-clinical tumor models and metastatic melanoma patients. However, no such reports exist for patients with metastatic lung adenocarcinoma. We report the first abscopal response in a treatment-refractory lung cancer patient treated with radiotherapy and ipilimumab. A post-treatment increase in tumor-infiltrating cytotoxic lymphocytes, tumor regression, and normalization of tumor markers was observed. One year after treatment with concurrent radiotherapy and ipilimumab the patient is without evidence of disease.

• Authors: Encouse B Golden, Sandra Demaria, Peter B Schiff, Abraham Chachoua, Silvia C Formenti
• Journal: Cancer immunology research (Cancer Immunol Res) Vol. 1 Issue 6 Pg. 365-72 (Dec 2013) ISSN: 2326-6074 [Electronic] United States
• PMID: 24563870 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents
• Ipilimumab

Topics

• Adenocarcinoma (drug therapy, immunology, radiotherapy, secondary)
• Antibodies, Monoclonal (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, immunology, radiotherapy, secondary)
• Combined Modality Therapy
• Humans
• Ipilimumab
• Lymphocytes, Tumor-Infiltrating (drug effects, radiation effects)
• Male
• Middle Aged
• Positron-Emission Tomography
• Tomography, X-Ray Computed